Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CLINICAL MEASUREMENT - ANNOTATIONS

The Clinical Measurement Ontology (CMO), Measurement Methods Ontology (MMO), and Experimental Condition Ontology (XCO) are currently being developed at the Rat Genome Database. For more information about these vocabularies please see Shimoyama et al. Three ontologies to define phenotype measurement data. Front Genet. 2012;3:87. Epub 2012 May 28 or contact us (http://rgd.mcw.edu/contact/index.shtml).

Term:organ tumorous lesion incidence/prevalence measurement
go back to main search page
Accession:CMO:0000928 term browser browse the term
Definition:A measurement in which the number of individuals in a study population that display one or more tumorous lesion(s) of a particular organ at a point in time or develop such lesions within a determined period of time are compared to the total number of individuals in the study population. Often expressed as a percentage but could be expressed as a ratio. A tumorous lesion is a localized pathological change in structure of an organ or tissue due to injury or disease; especially one that is circumscribed and well defined, but which is or has the potential to become a tumor, that is, a neoplasm or new growth of tissue in which cell multiplication is more or less uncontrolled and progressive. Tumorous lesions include tumors, preneoplastic lesions, and hyperplastic lesions composed of histologically normal cells.


show annotations for term's descendants           Sort by:
 
mammary tumor incidence/prevalence measurement term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Mcs31 Mammary carcinoma susceptibility QTL 31 IDA RGD PMID:23967281 RGD:7794780 NCBI chr 9:77,813,894...111,552,878 JBrowse link
Q Mcs32 Mammary carcinoma susceptibility QTL 32 IDA RGD PMID:23967281 RGD:7794780 NCBI chr 1:115,540,693...238,914,717 JBrowse link
Q Mcs33 Mammary carcinoma susceptibility QTL 33 IDA RGD PMID:23967281 RGD:7794780 NCBI chr 5:131,345,754...166,875,058 JBrowse link
Q Mcs34 Mammary carcinoma susceptibility QTL 34 IDA RGD PMID:23967281 RGD:7794780
percentage of study population developing mammary tumors during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Emca4 Estrogen-induced mammary cancer QTL 4 IDA RGD PMID:16885383 RGD:1642522 NCBI chr 7:62,004,452...101,773,158 JBrowse link
Q Emca5 Estrogen-induced mammary cancer QTL 5 IDA RGD PMID:16885383 RGD:1642522 NCBI chr 3:43,827,364...169,034,231 JBrowse link
percentage of study population developing T-cell lymphomas during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Tls2 T-lymphoma susceptibility QTL 2 IDA RGD PMID:10360666 RGD:619600 NCBI chr 7:80,221,299...109,401,111 JBrowse link
Q Tls3 T-lymphoma susceptibility QTL 3 IDA RGD PMID:10360666 RGD:619600 NCBI chr10:51,774,612...95,600,334 JBrowse link
percentage of study population developing testis tumors during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Tescar1 Testicular tumor resistance QTL 1 IDA RGD PMID:15805257 RGD:1358944 NCBI chr11:1,041,931...66,113,562 JBrowse link
percentage of study population developing trigeminal nerve neurilemmomas during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Schws1 Schwannoma susceptibility QTL 1 IDA RGD PMID:16003739 RGD:1559300 NCBI chr10:40,035,094...102,359,817 JBrowse link
Q Schws2 Schwannoma susceptibility QTL 2 IDA RGD PMID:16003739 RGD:1559300
Q Schws3 Schwannoma susceptibility QTL 3 IDA RGD PMID:16003739 RGD:1559300 NCBI chr 3:118,839,124...163,839,124 JBrowse link
Q Schws4 Schwannoma susceptibility QTL 4 IDA RGD PMID:16003739 RGD:1559300 NCBI chr 6:83,190,345...106,747,639 JBrowse link
Q Schws7 Schwannoma susceptibility QTL 7 IDA RGD PMID:16003739 RGD:1559300 NCBI chr10:4,765,527...19,816,042 JBrowse link
Q Schws8 Schwannoma susceptibility QTL 8 IDA RGD PMID:25303613 RGD:11566050 NCBI chr 6:94,968,928...139,968,928 JBrowse link
Q Schws9 Schwannoma susceptibility QTL 9 IDA RGD PMID:25303613 RGD:11566050 NCBI chr 6:61,747,639...106,747,639 JBrowse link
percentage of study population developing ventral prostate tumorous lesions during a period of time term browser
Symbol Object Name Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
Q Prcs1 Prostate cancer susceptibility QTL 1 IDA RGD PMID:15805257 RGD:1358944 NCBI chr19:15,114,598...34,521,833 JBrowse link
Q Prcs2 Prostate cancer susceptibility QTL 2 IDA RGD PMID:15805257 RGD:1358944 NCBI chr20:4,606,607...17,617,956 JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  clinical measurement 2369
    disease population measurement 57
      disease incidence/prevalence measurement 57
        organ tumorous lesion incidence/prevalence measurement 18
          lung tumorous lesion incidence/prevalence measurement + 0
          pituitary gland tumorous lesion incidence/prevalence measurement + 0
          prostate tumorous lesion incidence/prevalence measurement + 2
          tumor incidence/prevalence measurement + 16
Path 2
Term Annotations click to browse term
  clinical measurement 2369
    organ measurement 485
      organ lesion measurement 140
        organ tumorous lesion measurement 108
          organ tumorous lesion incidence/prevalence measurement 18
            lung tumorous lesion incidence/prevalence measurement + 0
            pituitary gland tumorous lesion incidence/prevalence measurement + 0
            prostate tumorous lesion incidence/prevalence measurement + 2
            tumor incidence/prevalence measurement + 16
paths to the root